These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 32650586)

  • 1. Nutraceuticals in the Treatment of Pulmonary Arterial Hypertension.
    Sánchez-Gloria JL; Osorio-Alonso H; Arellano-Buendía AS; Carbó R; Hernández-Díazcouder A; Guzmán-Martín CA; Rubio-Gayosso I; Sánchez-Muñoz F
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32650586
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Peng Y; Dai J; Zhao YY
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review.
    Ruopp NF; Cockrill BA
    JAMA; 2022 Apr; 327(14):1379-1391. PubMed ID: 35412560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MnTBAP Reverses Pulmonary Vascular Remodeling and Improves Cardiac Function in Experimentally Induced Pulmonary Arterial Hypertension.
    Gomez-Puerto MC; Sun XQ; Schalij I; Orriols M; Pan X; Szulcek R; Goumans MJ; Bogaard HJ; Zhou Q; Ten Dijke P
    Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32531895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blueberry extract decreases oxidative stress and improves functional parameters in lungs from rats with pulmonary arterial hypertension.
    Türck P; Fraga S; Salvador I; Campos-Carraro C; Lacerda D; Bahr A; Ortiz V; Hickmann A; Koetz M; Belló-Klein A; Henriques A; Agostini F; da Rosa Araujo AS
    Nutrition; 2020 Feb; 70():110579. PubMed ID: 31743815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pulmonary vasodilators can lead to various complications in pulmonary "arterial" hypertension associated with congenital heart disease.
    Chida-Nagai A; Sagawa K; Tsujioka T; Fujimoto T; Taniguchi K; Sasaki O; Izumi G; Yamazawa H; Masaki N; Manabe A; Takeda A
    Heart Vessels; 2020 Sep; 35(9):1307-1315. PubMed ID: 32285188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current status of pulmonary arterial hypertension in Korea.
    Jang AY; Chung WJ
    Korean J Intern Med; 2019 Jul; 34(4):696-707. PubMed ID: 31272141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostaglandin and prostaglandin receptors: present and future promising therapeutic targets for pulmonary arterial hypertension.
    Zeng C; Liu J; Zheng X; Hu X; He Y
    Respir Res; 2023 Nov; 24(1):263. PubMed ID: 37915044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perillyl alcohol suppresses monocrotaline-induced pulmonary arterial hypertension in rats via anti-remodeling, anti-oxidant, and anti-inflammatory effects.
    Beik A; Najafipour H; Joukar S; Rajabi S; Iranpour M; Kordestani Z
    Clin Exp Hypertens; 2021 Apr; 43(3):270-280. PubMed ID: 33322932
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment Discontinuation or Interruption in Pulmonary Arterial Hypertension.
    Narechania S; Torbic H; Tonelli AR
    J Cardiovasc Pharmacol Ther; 2020 Mar; 25(2):131-141. PubMed ID: 31594400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pulmonary Arterial Hypertension: a Pharmacotherapeutic Update.
    Coons JC; Pogue K; Kolodziej AR; Hirsch GA; George MP
    Curr Cardiol Rep; 2019 Nov; 21(11):141. PubMed ID: 31758342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Search for Disease-Modifying Therapies in Pulmonary Hypertension.
    Woodcock CC; Chan SY
    J Cardiovasc Pharmacol Ther; 2019 Jul; 24(4):334-354. PubMed ID: 30773044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pulmonary arterial hypertension specific therapy: The old and the new.
    Zolty R
    Pharmacol Ther; 2020 Oct; 214():107576. PubMed ID: 32417272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Considerations for Inotrope and Vasopressor Use in Critically Ill Patients With Pulmonary Arterial Hypertension.
    Adie SK; Abdul-Aziz AA; Ketcham SW; Moles VM
    J Cardiovasc Pharmacol; 2022 Jan; 79(1):e11-e17. PubMed ID: 34654789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of Src activation reverses pulmonary vascular remodeling in experimental pulmonary arterial hypertension via Akt/mTOR/HIF-1 signaling pathway.
    Liu P; Gu Y; Luo J; Ye P; Zheng Y; Yu W; Chen S
    Exp Cell Res; 2019 Jul; 380(1):36-46. PubMed ID: 30802452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of masitinib compared with tadalafil for the treatment of monocrotaline-induced pulmonary arterial hypertension in rats.
    Leong ZP; Hikasa Y
    Vascul Pharmacol; 2019; 122-123():106599. PubMed ID: 31629919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective effects of dioscin on vascular remodeling in pulmonary arterial hypertension via adjusting GRB2/ERK/PI3K-AKT signal.
    Yang Y; Yin L; Zhu M; Song S; Sun C; Han X; Xu Y; Zhao Y; Qi Y; Xu L; Peng JY
    Biomed Pharmacother; 2021 Jan; 133():111056. PubMed ID: 33378960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NTP42, a novel antagonist of the thromboxane receptor, attenuates experimentally induced pulmonary arterial hypertension.
    Mulvaney EP; Reid HM; Bialesova L; Bouchard A; Salvail D; Kinsella BT
    BMC Pulm Med; 2020 Apr; 20(1):85. PubMed ID: 32252727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-181b-5p inhibits endothelial-mesenchymal transition in monocrotaline-induced pulmonary arterial hypertension by targeting endocan and TGFBR1.
    Zhao H; Wang Y; Zhang X; Guo Y; Wang X
    Toxicol Appl Pharmacol; 2020 Jan; 386():114827. PubMed ID: 31734320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunity and inflammation in pulmonary arterial hypertension: From pathophysiology mechanisms to treatment perspective.
    Wang RR; Yuan TY; Wang JM; Chen YC; Zhao JL; Li MT; Fang LH; Du GH
    Pharmacol Res; 2022 Jun; 180():106238. PubMed ID: 35504356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.